OBJECTIVE: To probe into the clinical efficacy of reteplase combined with low molecular weight heparin calcium in treatment of acute myocardial infarction .METHODS:104 patients with acute myocardial infarction admitted into Wuhan No .1 Hospital from Jun .2014 to Jun.2016 were selected and divided into observation group and control group via random number table , with 52 cases in each .The control group was given reteplase injection combined with heparin sodium injection , while the observation group was given reteplase combined with low molecular weight heparin calcium for injection .Clinical efficacy , clinical indices and incidences of complications of two groups were observed .RESULTS:The total effective rates of observation group and control group were respectively 92.31％(48/52) and 88.46％(46/52), the difference had no statistical significance (P>0.05); the relief time of chest pain and 50％fall back time of ST segment of observation group were significantly shorter than those of the control group , with statistically significant differences ( P0.05 ); the incidence of complications of observation group ( 9.62％, 5/52 ) was significantly lower than that of the control group ( 25.00％, 13/52 ) , with statistically significant difference ( P 0.05);观察组患者胸痛缓解时间和静息心电图ST段回降>50％时间明显短于对照组,差异均有统计学意义(P0.05);观察组患者并发症发生率为9.62％(5/52),明显低于对照组的25.00％(13/52),差异有统计学意义(P<0.05).结论:瑞替普酶联合低分子肝素钙治疗急性心肌梗死的疗效显著,可改善患者症状,且并发症少,安全性高.
展开▼
